AzTrials
AzTrials

EviscerationNCT06962384

Comparing Posterior Release Sclerotomy With Conventional Evisceration Surgery.

A study testing Posterior release sclerotomy and Conventional Ball Implantation in people with Evisceration and Ocular Trauma, run by Fayoum University Hospital at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The primary objective of this interventional study is to compare posterior release sclerotomy in the scleral cup with conventional ball implantation during evisceration, focusing on intraoperative feasibility, postoperative outcomes, and implant stability. Specific objectives include: 1. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Evisceration, Ocular Trauma, Blind Painful Eye
What is being tested?
Posterior release sclerotomy and Conventional Ball Implantation
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
80 participants
Where
1 siteEgypt
Study dates
1 May 2024to 28 Apr 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Aged 18 years or older
  • Indication for evisceration due to a non-malignant cause, such as painful blind eye, severe ocular trauma, end-stage glaucoma, or phthisis bulbi
  • Adequate scleral integrity to allow for ball implantation
  • No history of previous intraocular surgery or scleral weakening disorders

Who cannot join

  • Orbital malignancy or suspected intraocular tumor
  • Active ocular or periocular infection
  • History of radiation therapy to the orbit
  • Severe scleral thinning that contraindicates scleral preservation
  • Presence of autoimmune disease affecting wound healing
  • Psychiatric disorders affecting compliance with postoperative care

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Fayoum university hospital

    Al Fayyum

Other trials in Egypt

About this study

Official title: Comparative Analysis of Posterior Release Sclerotomy vs Conventional Ball Implantation in Evisceration Surgery

The primary objective of this interventional study is to compare posterior release sclerotomy in the scleral cup with conventional ball implantation during evisceration, focusing on intraoperative feasibility, postoperative outcomes, and implant stability.

Specific objectives include:

  1. Assessing the rate of implant migration and extrusion.
  2. Evaluating the long-term stability of the implant within the scleral shell.
  3. Investigating the occurrence of complications such as exposure or infection.
  4. Analyzing the functional and anatomical outcomes.
  5. Comparing patient satisfaction and quality of life measures.
Read the detailed description

Evisceration is a widely performed ocular procedure aimed at removing intraocular contents while preserving the scleral shell and extraocular muscles. The primary goal of evisceration is to provide a structurally stable orbital implant, ensuring optimal prosthetic motility and cosmetic appearance. Traditional evisceration with ball implantation often presents complications related to limited space within the scleral cavity, potentially leading to implant extrusion or migration.

A key advancement in evisceration techniques is posterior release sclerotomy within the scleral cup, which aims to expand the intraocular space and facilitate primary ball implantation. By creating a controlled posterior opening, this method is hypothesized to reduce intraoperative resistance to implant insertion, minimize excessive intraocular pressure, and decrease postoperative complications such as extrusion or exposure. However, comparative studies on the effectiveness of posterior release sclerotomy versus conventional ball implantation remain limited.

Conventional evisceration techniques involve creating a scleral incision to accommodate the ball implant, often requiring significant manipulation to fit the prosthesis securely. The resultant tight fit can lead to ischemic changes, delayed healing, and an increased risk of implant extrusion. In contrast, posterior release sclerotomy allows for better distribution of intraocular pressure and improved accommodation of the implant, potentially reducing postoperative complications.

Several studies have highlighted the importance of scleral integrity and orbital volume restoration in optimizing prosthetic movement and overall aesthetic outcomes. Ensuring adequate implant placement without undue pressure on the scleral shell is a crucial factor in preventing long-term complications such as conjunctival dehiscence or implant migration. Posterior release sclerotomy may offer a surgical advantage by providing additional space for implantation, reducing undue pressure, and preserving the scleral integrity.

Despite these theoretical advantages, clinical evidence comparing posterior release sclerotomy with conventional ball implantation remains scarce. Previous retrospective studies suggest that modified techniques may enhance surgical ease and reduce complications.

The present study aims to compare posterior release sclerotomy in the scleral cup with conventional ball implantation during evisceration, focusing on intraoperative feasibility, postoperative outcomes, and implant stability.

This prospective, randomized, controlled trial will be conducted at the Department of Ophthalmic Surgery, Factuality of medicine, Fayum university.

The study will enroll patients requiring evisceration to one of two groups:

  • Posterior Release Sclerotomy Group (PRS Group): Underwent evisceration with posterior release sclerotomy before primary ball implantation.
  • Conventional Ball Implantation Group (CBI Group): Underwent standard evisceration with direct ball implantation without posterior sclerotomy.
  1. History Taking
  • Ocular History: Duration and cause of blindness, previous surgeries/trauma, pain, inflammation, or medication use.
  • Systemic History: Comorbidities (diabetes, hypertension, autoimmune diseases), history of radiation or malignancies.
  • Medication History: Use of anticoagulants or immunosuppressants affecting bleeding or healing.
  1. Clinical Examination
  • Visual Acuity Testing (if applicable)
  • Slit-lamp Examination: Corneal clarity, conjunctival health, intraocular inflammation.
  • Tonometry: Intraocular pressure measurement.
  • Fundus Examination: To rule out intraocular pathology.
  • External Examination: Eyelid position, orbital contour, tenderness, masses. 3. Preoperative Investigations
  • CBC, Coagulation Profile .
  • FBS \& HbA1c.
  • Orbital Ultrasound (if needed) : Assess scleral integrity.
  • CT Orbit (if indicated): For suspected fractures, tumors.

Surgical Procedure All surgeries were performed under general anesthesia by an experienced ophthalmic surgeon. Standard sterile techniques were followed, and appropriate antibiotic prophylaxis was administered preoperatively.

  1. Preoperative Preparation
  • Antibiotic prophylaxis: Intravenous cefazolin (1g) was given 30 minutes before surgery.
  • The surgical site was prepared with povidone-iodine 5%, and a lid speculum was placed.
  • A 360-degree conjunctival peritomy was performed using Westcott scissors, followed by meticulous dissection to expose the scleral shell.
  1. Evisceration Procedure
  2. Group-Specific Implantation Procedures Posterior Release Sclerotomy Group (PRS Group) Conventional Ball Implantation Group (CBI Group)
  • No posterior sclerotomy was performed.
  • The implant was inserted directly into the scleral cup, requiring greater force to accommodate the implant within the available space.
  1. Closure and Conformer Placement
  • The scleral flaps were sutured in a purse-string fashion using non-absorbable 6-0 sutures.
  • The conjunctiva was closed with interrupted 8-0 Vicryl sutures to ensure proper healing.
  • A temporary conformer was placed inside the orbit to maintain the fornices and prevent conjunctival contracture.
  • The surgical site was padded and bandaged to provide adequate protection and minimize postoperative swelling.
  1. Postoperative Care
  • Patients were monitored for early complications (e.g., bleeding, infection).
  • Topical antibiotics and corticosteroids were prescribed postoperatively.
  • Patients were followed up at 1 week, 1 month, and 6 months to assess implant stability, healing, and cosmetic outcomes.

Outcome Measures Primary Outcome

  • Implant extrusion/migration rate within 6 months Secondary Outcomes
  • Surgical ease and intraoperative difficulty score
  • Postoperative pain (Visual Analogue Scale score)
  • Healing time (conjunctival re-epithelialization)
  • Implant stability and motility
  • Cosmetic outcome (patient satisfaction scores, prosthesis motility)

Ethical consideration:

All the individuals included in the study will be informed about the procedures regarding the study and will be informed of their rights to refuse participation or withdraw from the study without having to give reasons. Participants will be guaranteed anonymity and all information provided would be treated with confidentiality. The ethical approval of the faculty of medicine, fayoum university research ethical committee (REC) will be obtained prior to the beginning of the work.

Being tested
Posterior release sclerotomy, Conventional Ball Implantation
Keywords
Evisceration, Ball implantation, Posterior release sclerotomy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Posterior release sclerotomyProcedure or surgery

    • A 360-degree radial scleral incision was made, and an evisceration spoon was used to remove intraocular contents.
    • The scleral shell was cauterized to eliminate any residual uveal tissue.
    • Any remaining necrotic or inflamed tissue was debrided to ensure a clean surgical field and minimize postoperative complications.

    Posterior Release Sclerotomy Group (PRS Group)

    • A posterior sclerotomy (2-3 mm) was created at the posterior pole of the scleral shell using a crescent blade.
    • This sclerotomy expanded the intraocular space, reducing intraoperative resistance during implant insertion.
    • The spherical implant was gently placed within the expanded scleral shell, ensuring minimal stress on the tissue.
  • Conventional Ball ImplantationProcedure or surgery

    • A 360-degree radial scleral incision was made, and an evisceration spoon was used to remove intraocular contents.
    • The scleral shell was cauterized to eliminate any residual uveal tissue.
    • Any remaining necrotic or inflamed tissue was debrided to ensure a clean surgical field and minimize postoperative complications.
    • No posterior sclerotomy was performed.
    • The implant was inserted directly into the scleral cup, requiring greater force to accommodate the implant within the available space.
Study groups in NCT06962384
Study groupRoleWhat they receive
Posterior Release Sclerotomy Group (PRS Group)ExperimentalA key advancement in evisceration techniques is posterior release sclerotomy within the scleral cup, which aims to expand the intraocular space and facilitate primary ball implantation. By creating a controlled posterior opening, this method is hypothesized to reduce intraoperative resistance to implant insertion, minimize excessive intraocular pressure, and decrease postoperative complications such as extrusion or exposure
Receives: Procedure: Posterior release sclerotomy
Conventional Ball Implantation Group (CBI Group)ExperimentalConventional evisceration techniques involve creating a scleral incision to accommodate the ball implant, often requiring significant manipulation to fit the prosthesis securely. The resultant tight fit can lead to ischemic changes, delayed healing, and an increased risk of implant extrusion.
Receives: Procedure: Conventional Ball Implantation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. • Implant extrusion/migration rate within 6 months

    The primary outcome measure was implant stability, assessed clinically and through imaging at 1, 3, and 6 months postoperatively to review any signs of implant migration or extrusion as well as signs of conjunctival erosion.

    Measured: Through study completion, an average of 6 months

Secondary outcomes (3)
  1. Patient satisfaction with implant motility

    Assessed through a standardized questionnaire. Measuring patient satisfaction by giving a score from 1-5, where 5 means excellent and 1 means very poor.

    Measured: From enrollment to the end of the follow up period after 6 months

  2. Postoperative pain

    The Quality of Life Score was determined using a Visual Analog Scale (VAS), which is a straight horizontal line, usually 10 mm. The ends of which are described as the extreme limits of the parameter to be measured oriented from the left (worst) to the right (best).

    Measured: From enrollment to the end of the follow up period after 6 months

  3. Postoperative complications

    Measured: From enrollment to the end of the follow up period after 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 May 2025
  2. Study start1 May 2024
  3. Primary completion28 Apr 2025
  4. Study completion28 Apr 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
80 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06962384
Sponsor's protocol ID
FUH
Status last verified
Jun 2025
First submitted
30 Apr 2025
Last updated
3 Jun 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Posterior release sclerotomy and Conventional Ball Implantation in people with Evisceration and Ocular Trauma, run by Fayoum University Hospital at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

• Implant extrusion/migration rate within 6 months (time frame: Through study completion, an average of 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Jun 2025; AzTrials last refreshed its copy on 30 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in